Company Overview - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - The company is a leading developer of innovative small molecule inhibitors for autoimmune and inflammatory diseases, focusing on the JAK-STAT signaling pathway [3] Product Pipeline - The core products include LNK01001, a highly selective second-generation JAK1 inhibitor; LNK01004, a potential first-in-class third-generation soft pan-JAK inhibitor; and LNK01006, a cutting-edge TYK2 inhibitor targeting central nervous system diseases [3][4] - The company has developed an innovative proprietary IsoNova protein degradation platform, enhancing target selectivity and reducing off-target effects, with potential applications beyond autoimmune diseases to oncology and neurodegenerative diseases [4] Market Potential - The global JAK inhibitor market is projected to grow from $5.5 billion in 2019 to $13.9 billion by 2024, with expectations to reach $25.6 billion by 2028 and $40.8 billion by 2033 [6][16] - In China, the JAK inhibitor market is expected to expand from RMB 400 million in 2019 to RMB 3.8 billion by 2024, with forecasts of RMB 17.1 billion by 2028 and RMB 46.5 billion by 2033 [6][16] Clinical Development - As of the last feasible date, the company has advanced its core candidates LNK01001 and LNK01004 into clinical stages, with LNK01001 undergoing multiple Phase III trials and LNK01004 having completed Phase II trials in China [7][8] - The company aims to maximize patient efficacy and safety through the development of innovative candidates, with several preclinical candidates also in the pipeline [8] Financial Performance - The company reported other income of RMB 20.57 million, RMB 16.98 million, and RMB 54.78 million for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [9] - The annual losses for the same periods were approximately RMB 260 million, RMB 312 million, and RMB 145 million [10] - Research and development expenditures were approximately RMB 186 million, RMB 223 million, and RMB 121 million for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [11] Industry Overview - The global market for autoimmune and inflammatory disease drugs has grown from $133 billion in 2019 to $160.8 billion in 2024, with a projected CAGR of 3.9% [12] - The Chinese market for autoimmune and inflammatory disease drugs is expected to grow from RMB 42.7 billion in 2019 to RMB 66.5 billion by 2024, with a CAGR of 9.3% [13][14]
新股消息 | 凌科药业递表港交所 核心产品LNK01001有潜力成为最佳的第二代JAK1抑制剂